Vnitr Lek 2010, 56(3):173-175

Non-alcoholic steatosis and steatohepatitis - editorial

R. Brůha
IV. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Aleš Žák, DrSc.

Received: March 3, 2010; Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brůha R. Non-alcoholic steatosis and steatohepatitis - editorial. Vnitr Lek. 2010;56(3):173-175.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219. Go to original source... Go to PubMed...
    2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317. Go to original source... Go to PubMed...
    3. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007; 133: 1814-1820. Go to original source... Go to PubMed...
    4. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver dinase: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850. Go to original source... Go to PubMed...
    5. Lewis GF, Carpentier A, Adeli K et al. Disordered fat storage and mobilisation in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229. Go to original source... Go to PubMed...
    6. Day C, James O Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845. Go to original source... Go to PubMed...
    7. Diehl AM, Li ZP, Lin HZ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306. Go to original source... Go to PubMed...
    8. Hui J, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alfa or adiponectin? Hepatology 2004; 40: 19-22. Go to original source... Go to PubMed...
    9. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117. Go to original source... Go to PubMed...
    10. Caldwell SH, Oelsner DH, Lezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669. Go to original source... Go to PubMed...
    11. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3: 1260-1268. Go to original source... Go to PubMed...
    12. Cortez-Pinto H, Baptista A, Camil E et al. Nonalcoholic steatohepatitis clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-179. Go to original source... Go to PubMed...
    13. Dousa M, Zima T, Bruha R et al. Sensitivity and specificity of CDT in the evaluation of alcohol abuse in cirrhotic patients. Gut 2006; 55 (Suppl. No V): A 307.
    14. Dunn W, Angulo P, Sanderson S et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006; 131: 1057-1063. Go to original source... Go to PubMed...
    15. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419. Go to original source... Go to PubMed...
    16. Bugianesi E, Manzini P, D'Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-187. Go to original source... Go to PubMed...
    17. Loria P, Lonardo A, Leonardi F et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48: 2173-2181. Go to original source... Go to PubMed...
    18. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistence and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. Go to original source... Go to PubMed...
    19. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474. Go to original source... Go to PubMed...
    20. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873. Go to original source... Go to PubMed...
    21. Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602. Go to original source... Go to PubMed...
    22. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107. Go to original source... Go to PubMed...
    23. Bellentani S, Dalle Grave R, Suppini A et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008; 47: 746-754. Go to original source... Go to PubMed...
    24. Angelico F, Burattin M, Alessandri C et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007: CD005166. Go to original source...
    25. Capanni M, Calella F, Biagini MR et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-1151. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.